

The team (JunHe) provides services in a variety of industries, including automotive, pharmaceuticals, life sciences, technologies and transportation. Actively participates in the drafting and amendment of relevant laws and regulations.

—Chambers Asia-Pacific 2020

## Life Science and Health

**As one of the few domestic teams that provide specialized legal services in the life sciences and healthcare industry, JunHe offers comprehensive, full-range professional services for various clients in the industry, including multi-national corporations, private equity/venture investment institutions, medical institutions, listed companies, large- and medium-sized enterprises and innovative enterprises with growing capacity.**

### Our Team

JunHe has more than 30 partners with extensive experience in the provision of specialized legal services in the life sciences and healthcare industry, including several partners who have practiced in international law firms and have extensive practical experience in various sectors of the industry. JunHe's life sciences and healthcare team is a cross-functional cooperation team in JunHe's internal structure, and its members include legal professionals who have long been practicing in the pharmaceutical and medical industries, with a range of experience such as corporate and M&A, capital market, private equity/venture investment, intellectual property rights, compliance, and dispute resolution.

### One-Stop Service Rooted in the Industry

Based on our in-depth understanding in the industry and wide-ranging client relationships, with our high sensitivity to business operations, product features, industry trends, and to the relevant legal issues, we are equipped to fully understand the commercial intentions of our clients, and make accurate legal judgments on the business plans of our clients, as well as propose strategic suggestions that are operable in practice.

JunHe, founded in Beijing in 1989, is one of the first private partnership law firms in China. Since its establishment, JunHe has grown to be one of the largest and most recognized Chinese law firms. The firm has thirteen offices around the world and a team comprised of more than 880 professionals, including over 240 partners and legal counsel, as well as over 640 associates and legal translators.

In regard to the industries of pharmaceuticals and medical devices, we are able to provide regulatory services for clinical trials and product registrations and IP transaction services related to product development and license; with regard to corporate finance, we are able to provide legal services for private placement/venture investment and capital market for enterprises in the industry; as for the daily operation of enterprises, we are able to provide legal services related to compliance, labor, taxation, and dispute resolution. Benefiting from JunHe's unified internal management, cross-sector and cross-regional lawyers are able to work closely with each other under unified coordination and guidance, and provide comprehensive and high quality services to our clients.



(JunHe) Acts for clients in a variety of industries, and is increasingly active in the pharmaceutical and health-care sectors.

—Chambers Asia-Pacific 2020

### Selected Deals

#### M & A and Joint Venture

- Bayer's Acquisition of Dihon Pharmaceutical Group – JunHe represented Dihon Pharmaceutical Group throughout the entire transaction. The legal services provided included anti-monopoly notification, due diligence investigation on the seller, business negotiations and contract signing. This transaction was recognized as the 2015 "Deal of the Year" by China Business Law as an extremely high value transaction, amounting to RMB 3.6 billion.
- Stryker's Acquisition of Trauson Holdings Company Limited – JunHe represented Stryker Corporation, a company listed on New York Stock Exchange, and a giant in global orthopedic and medical technology, in the acquisition of a Hong Kong listed company – Trauson Holdings Company Limited, for a total amount of 5.9 billion HK dollars.
- A joint venture pharmaceuticals company and a wholly-owned pharmaceuticals distribution enterprise established by Zhejiang Hisun Pharmaceutical Co., Ltd. and Hisun Pfizer Pharmaceuticals Company Limited – JunHe as the sole external legal advisor of Zhejiang Hisun Pharmaceutical Co., Ltd. assisted throughout the entire process of establishing a joint venture pharmaceuticals company with Hisun Pfizer Pharmaceuticals by using its part of pharmaceutical assets and business, and also establishing a wholly-owned drug distribution subsidiary under the joint venture company.

#### Capital Market

- BeiGene, Ltd. (BGNE) listed in NSDAQ – JunHe as the Chinese legal advisor of the co-sponsor and underwriter participated throughout the entire process of listing of BGNE, an enterprise in China immune anti-tumor drug R&D sector, on the NSDAQ on February 8, 2016. BGNE raised more than 158 million US dollars in this IPO.
- Golden Throat Holdings Group Limited listed on the Main Board of The Stock Exchange of Hong Kong Limited – JunHe as the Chinese legal counsel of the sponsor participated in the initial public offering of common stocks of Golden Throat on July 15, 2015, valued at 835 million HK dollars.
- 360Buy and Shanghai Pharma jointly established an online pharmaceuticals sales platform – As the legal advisor of 360Buy, JunHe participated in the whole process of investment in Shanghai Medical Health Cloud by 360Buy, Shanghai Pharma Distribution Holdings Co., Ltd., and Beijing Harmony Growth Investment Center valued at RMB 1.1 billion.
- Tencent Holdings invested www.guahao.com and www.dxy.cn – In 2014 and 2015, JunHe represented Tencent in the two rounds of venture investment of www.guahao.com (which was later changed to We Doctor Group) with tens of millions of US dollars for each round of funding. It also represented Tencent in 2014 in the strategic investment of www.dxy.cn, an online medical information website with tens of thousands of US dollars.

PRC Firm of the Year -  
Healthcare & Life Sciences  
2017

Deal of the Year - Harbin Pharma's  
\$300M Investment in GNC  
2018

China Law & Practice Awards

Deals of the Year - JD Health's US\$1  
billion series A Financing  
2020

Deals of the Year -  
Bayer's Acquisition of all Shares  
of Dihon Pharmaceutical Group  
2015

Deals of the Year -  
Anti-Dumping Investigation by  
MOFCOM of Haemodialysis Control  
Unit Originated from EU and Japan  
2015

Deals of the Year - Anti-Monopol/  
Merger Control Notification  
on Thermo Fisher's Acquisition  
of Life Technologies Corporation  
2014

China Business Law Deals of the Year